BRAF and melanoma: However, despite several trials and studies having proven the efficacy of immuno checkpoint inhibitors (Moser et al., 2019; Pavlick et al., 2019) and targeted therapies in OS, no direct comparison has been performed so far, and the choice between the two therapeutic approaches in BRAF mutated melanoma is still debated.